2,975 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by SVB Wealth LLC

SVB Wealth LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 2,975 shares of the medical device company’s stock, valued at approximately $231,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Jennison Associates LLC raised its stake in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after acquiring an additional 6,544,102 shares in the last quarter. Congress Asset Management Co. grew its position in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD purchased a new position in DexCom during the 4th quarter worth $96,507,000. Westfield Capital Management Co. LP grew its position in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after purchasing an additional 739,000 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 0.6 %

Shares of NASDAQ DXCM opened at $81.96 on Thursday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm has a 50-day moving average price of $84.90 and a 200 day moving average price of $76.94. The stock has a market capitalization of $32.03 billion, a price-to-earnings ratio of 57.31, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on DXCM shares. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company raised their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock worth $3,309,794 over the last 90 days. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.